China Anesthesia and Respiratory Devices Market Outlook to 2021

1
Non-Small Cell Lung Cancer Therapeutics in Major
Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates
A Competitive Second-Line
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
TELEPHONE [phone]E-MAIL
sales_at_researchbeam.com
Published on Oct 2014
2


Report Overview

• Summary
• Non-Small Cell Lung Cancer (NSCLC) is the second
  most common cancer globally, and the most common
  cause of cancer-related mortality. Such a poor
  outlook, particularly for patients with advanced
  disease, has created a pressing need for improved
  therapeutic options. The NSCLC market is
  undergoing a gradual change from a focus on
  generic chemotherapy regimens to complex
  treatment landscape based on different NSCLC
  subtypes and the presence of various molecular
  aberrations. In the current market, patients with
  non-squamous histology can be treated with more
  efficacious therapies such as Alimta
  (pemetrexed), while patients harboring activating
  mutations in EGFR or ALK can be prescribed
  targeted therapy. While the NSCLC developmental
  pipeline must aim to improve the outlook for all
  patients, there is currently a lack of options
  for patients with squamous cell histology or
  other detectable molecular characteristics
  besides EFGR and ALK mutations.
• Read More At http//www.researchbeam.com/non-smal
  l-cell-lung-cancer-therapeutics-in-major-developed
  -to-2021-emergence-of-immunotherapies-drives-growt
  h-and-creates-a-competitive-second-line-market

3


Table of Content
1 Table of Contents 51.1 List of Tables 61.2
List of Figures 7 2 Introduction 82.1 Disease
Introduction 82.2 Epidemiology 9 3 Marketed
Products 293.1 Overview 293.2 Chemotherapies
29 4 NSCLC Pipeline 404.1 Overview 404.2
Mechanisms of Action and Targets in the Pipeline
43
4


Table of Content
5 Market Forecast 815.1 Geographical Markets
815.2 Drivers and Barriers 93 6 Strategic
Consolidations 956.1 Major Licensing Deals
956.2 Major Co-Development Deals 99 7 Appendix
1047.1 References 1047.2 Abbreviations
108 Enquire At http//www.researchbeam.com/no
n-small-cell-lung-cancer-therapeutics-in-major-dev
eloped-to-2021-emergence-of-immunotherapies-drives
-growth-and-creates-a-competitive-second-line-mark
et/enquire-about-report
5



FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/non-small-cell-lung-ca
ncer-therapeutics-in-major-developed-to-2021-emerg
ence-of-immunotherapies-drives-growth-and-creates-
a-competitive-second-line-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com